Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (735)	9/13/2000 6:57:51 PM
From: scaram(o)uche	Respond to of 1475

I have always believed in the potential...... Inhibition of Leukemia Progression in Rats by the Graft Versus Host Reaction, Richard C. Harmon and Yoko Mullen. Fed Proc. 35, 312 (1976). That's just an abstract. I never wrote the work up and submitted it (that's why I'm an investor instead of a professor some place..... I did that with study after study..... dumb, but.... hey, if there weren't people like me around, nobody else would look as outstanding...... :-). Dr. Mullen bugged me for a long time, and then gave up. Wish that I'd have had my act together, as it was a ton of work, what I considered to be good work. Far from real world, this is parent to F1. No conditioning of the host is necessary. It was very, very early work, without practical application.

To: sim1 who wrote (735)	9/13/2000 7:05:59 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

but the relevant antigens (tumor-specific antigens, the recipient's histocompatibility antigens, or both) have not been identified. Some of the GvH rats in my study survived leukemia challenge. When those animals were again challenged with the same spontaneous leukemia (which I had isolated and frozen down, in large quantity, after only a single passage in a Lewis rat), they died at the same time as age-matched controls. This argues -- not strongly, by any means -- against "tumor-specific".